Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

With the human immunodeficiency virus type 1 (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clinical trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTHr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clinical studies.

Original publication

DOI

10.1099/vir.0.80481-0

Type

Journal article

Journal

J Gen Virol

Publication Date

02/2005

Volume

86

Pages

349 - 354

Keywords

Animals, DNA, Viral, Drug Evaluation, Preclinical, Female, HIV Infections, HIV-1, Mice, Mice, Inbred BALB C, Replicon, Semliki forest virus, T-Lymphocytes, Vaccination, Vaccines, DNA, Viral Vaccines